XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 25.78%8.88B | 31.16%2.81B | 26.14%2.16B | 20.72%2.05B | 23.41%1.86B | 26.07%7.06B | 23.57%2.14B | 25.48%1.71B | 30.81%1.69B | 25.25%1.51B |
Operating revenue | 25.78%8.88B | 31.16%2.81B | 26.14%2.16B | 20.72%2.05B | 23.41%1.86B | 26.07%7.06B | 23.57%2.14B | 25.48%1.71B | 30.81%1.69B | 25.25%1.51B |
Cost of revenue | 24.34%4.41B | 34.94%1.46B | 28.41%1.04B | 16.41%1B | 14.29%904M | 24.56%3.55B | 15.47%1.08B | 15.48%813M | 34.43%859M | 39.75%791M |
Gross profit | 27.23%4.47B | 27.31%1.35B | 24.08%1.12B | 25.15%1.05B | 33.47%957M | 27.63%3.52B | 33.08%1.06B | 36.10%901M | 27.29%835M | 12.38%717M |
Operating expense | -5.46%3.4B | 14.75%887M | 7.19%835M | -28.91%804M | -4.29%871M | 0.48%3.59B | -21.60%773M | -22.72%779M | 33.69%1.13B | 23.64%910M |
Selling and administrative expenses | 5.38%1.8B | 10.31%460M | 3.01%445M | -8.63%413M | 18.29%485M | -11.71%1.71B | -18.55%417M | -22.44%432M | -1.09%452M | -0.49%410M |
-Selling and marketing expense | 14.18%1.39B | 9.78%348M | 12.20%331M | 9.97%353M | 25.78%361M | -0.81%1.22B | 6.38%317M | -2.32%295M | -1.83%321M | -5.28%287M |
-General and administrative expense | -16.50%410M | 12.00%112M | -16.79%114M | -54.20%60M | 0.81%124M | -30.65%491M | -53.27%100M | -46.27%137M | 0.77%131M | 12.84%123M |
Research and development costs | -20.98%1.37B | 12.86%351M | 6.07%332M | -46.14%349M | -26.86%335M | 15.10%1.73B | -29.32%311M | -24.03%313M | 86.74%648M | 50.66%458M |
Other operating expenses | 49.34%227M | 68.89%76M | 70.59%58M | 35.48%42M | 21.43%51M | 12.59%152M | 32.35%45M | -12.82%34M | -26.19%31M | 110.00%42M |
Operating profit | 1,478.21%1.08B | 60.90%465M | 131.97%283M | 181.42%241M | 144.56%86M | 90.51%-78M | 253.72%289M | 135.26%122M | -55.79%-296M | -96.94%-193M |
Net non-operating interest income expense | 27.80%308M | 5.88%72M | 22.22%77M | 37.93%80M | 221.33%241M | 78.95%68M | 215.00%63M | 383.33%58M | ||
Non-operating interest income | 27.80%308M | 5.88%72M | 22.22%77M | 37.93%80M | ---- | 221.33%241M | 78.95%68M | 215.00%63M | 383.33%58M | ---- |
Other net income (expense) | 3,740.91%845M | 172.00%884M | -7.92%500M | 88.90%-118M | -227.14%-342M | 100.76%22M | 170.04%325M | 223.21%543M | -4.22%-1.06B | 117.24%269M |
Gain on sale of security | -30.77%983M | 142.90%906M | -4.52%528M | -142.60%-118M | ---- | 149.37%1.42B | 180.39%373M | 229.17%553M | 127.16%277M | ---- |
Earnings from equity interest | -137.93%-138M | 54.17%-22M | -180.00%-28M | ---- | ---- | ---58M | ---48M | ---10M | ---- | ---- |
Special income (charges) | --0 | --0 | --0 | --0 | ---- | ---1.34B | --0 | --0 | ---1.34B | ---- |
-Write off | --0 | --0 | --0 | --0 | ---- | --1.34B | --0 | --0 | --1.34B | ---- |
Other non- operating income (expenses) | ---- | ---- | ---- | ---- | -227.14%-342M | ---- | ---- | ---- | ---- | --269M |
Income before tax | 1,104.32%2.23B | 108.36%1.42B | 18.13%860M | 115.60%203M | -436.84%-256M | 105.11%185M | 211.07%682M | 560.76%728M | -8.60%-1.3B | 104.60%76M |
Income tax | 294.34%209M | 412.00%128M | 220.00%32M | 220.00%32M | 112.50%17M | 132.52%53M | 177.78%25M | 900.00%10M | 66.67%10M | 104.47%8M |
Net income | 1,429.55%2.02B | 96.80%1.29B | 15.32%828M | 113.04%171M | -501.47%-273M | 103.82%132M | 205.46%657M | 551.57%718M | -8.89%-1.31B | 104.61%68M |
Net income continuous Operations | 1,429.55%2.02B | 96.80%1.29B | 15.32%828M | 113.04%171M | -501.47%-273M | 103.82%132M | 205.46%657M | 551.57%718M | -8.89%-1.31B | 104.61%68M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 1,429.55%2.02B | 96.80%1.29B | 15.32%828M | 113.04%171M | -501.47%-273M | 103.82%132M | 205.46%657M | 551.57%718M | -8.89%-1.31B | 104.61%68M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 1,429.55%2.02B | 96.80%1.29B | 15.32%828M | 113.04%171M | -501.47%-273M | 103.82%132M | 205.46%657M | 551.57%718M | -8.89%-1.31B | 104.61%68M |
Basic earnings per share | 1,470.00%1.57 | 95.84%0.9988 | 14.29%0.64 | 112.75%0.13 | -520.00%-0.21 | 103.66%0.1 | 204.08%0.51 | 566.67%0.56 | -7.37%-1.02 | 104.27%0.05 |
Diluted earnings per share | 1,450.00%1.55 | 95.84%0.9988 | 16.36%0.64 | 112.75%0.13 | -520.00%-0.21 | 103.66%0.1 | 204.08%0.51 | 558.33%0.55 | -7.37%-1.02 | 104.27%0.05 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |